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Summary: The cost of whole
genome sequencing is dropping
rapidly. There has been a great
deal of enthusiasm about the
potential for this technological
advance to transform clinical care.
Given the interest and significant
investment in genomics, this seems
an ideal time to consider what the
evidence tells us about potential
benefits and harms, particularly in
the context of health care policy.
The scale and pace of adoption of
this powerful new technology
should be driven by clinical need,
clinical evidence, and a commit-
ment to put patients at the centre
of health care policy.
Introduction
The upfront cost of sequencing an
individual’s entire genome is decreasing
rapidly. As a result, whole genome se-
quencing (WGS) is becoming feasible
for broad use in both research and
clinical care. (In this article, by WGS
we mean both WGS and other ap-
proaches, such as whole exome se-
quencing [WES] that, while not as
comprehensive as WGS, nevertheless
analyze a broad swath of the human
genome.) Not surprisingly, this tremen-
dous technological advance has resulted
in a great deal of enthusiastic specula-
tion about public uptake and clinical
application. There is significant mo-
mentum around the idea of using
WGS as a clinical tool in the near
future [1]. Indeed, some institutions are
already seeking to integrate WGS into
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their clinical programs [2]. The US
press has even suggested that the drive
for some institutions to develop the
necessary technological capacity is akin
to a genomics ‘‘arms race’’ [3,4].
Given this interest and the concomitant
investment in both genomic and clinical
translational research, we should consider
how best to frame health policy discussions
about the utilization of these emerging
sequencing technologies. For example, for
many genomic funding agencies and some
researchers, adopting WGS into routine
clinical care is an explicit aspiration.
Indeed, WGS has been called a revolu-
tionizing diagnostic tool [5,6] that will
have a profound impact on the practice of
medicine [7]. While inexpensive and
efficient, WGS is an impressive technolog-
ical achievement, with the potential to
serve as the foundation for new approach-
es to screening, diagnosis, risk prediction,
and prognostic platforms in clinical prac-
tice; the actual impact it will have on
health and health care systems is far from
certain.
In this article, we highlight policy issues
that warrant thought regarding the appli-
cations/uses of WGS in clinical care and
within health systems. As with any new
technology, decisions about clinical use
should, as much as possible, be based on
the best available evidence and on consid-
eration of potential benefits and harms [8].
History tells us that without careful
consideration of the social forces that
influence technological implementation
and their public and social costs, a less
than ideal utilization policy can emerge
[9,10]. As some seek to introduce WGS
into clinical use—including what has been
called a ‘‘genome-based assault on cancer’’
[4]—a detailed reflection on its clinical
applications seems warranted. Indeed, as
enthusiasm grows and speculation on a
range of applications intensifies, the timing
for this kind of policy analysis seems ideal.
Here we seek to highlight the most
promising areas for the application of
WGS, whilst considering areas where
claims of its clinical and social utility may
be overstated. We also consider, from a
health policy perspective, how best to
guide discussions about the implementa-
tion of this emerging technology.
Public and Scientific
Enthusiasm for WGS
Success stories of WGS abound in the
popular press [11,12]. Thousands of
individuals currently have their genomes
sequenced each year in the clinical,
research and, to a lesser extent, direct-to-
consumer context. And, in certain clinical
situations, WGS helps to provide a more
definitive diagnosis (e.g., in unusual and
rare conditions that seem likely to have a
genetic cause). For rare inherited condi-
tions and some cancers, WGS has even led
to improved medical management of
patients [13]. Given these early successes,
it is no surprise that there have been many
enthusiastic predictions about the possible
clinical value of WGS—particularly in the
context of personalized medicine. One
industry commentator, for example, has
claimed that the rise in cancer rates ‘‘can
be fixed’’ with genome sequencing and
personalized medicine [14]. What impact
might this type of discourse have on health
policy?
Scientific and public enthusiasm for an
emerging area is a common feature of the
innovation process [15]. This enthusiasm
and the associated public representations
help to build institutional momentum and
attract funding from both the public and
private sectors [16]—a process that is
particularly important for big, complex,
and expensive areas of scientific inquiry,
like genomics [17]. But research tells us
that this kind of enthusiasm can, for better
or worse, also impact how an area is
represented, including framing the specu-
lation about clinical utility and health
benefit.
There is a growing literature on how a
range of social forces and publication
trends can lead to exaggerated claims of
future clinical benefit [18–21]. It has, for
example, been noted that positive ‘‘spin’’
exists in peer-reviewed articles [22], insti-
tutional press releases [23], and the
popular press. Growing commercialization
and translation pressures, the need to
attract research support in a highly
competitive funding environment, and
the simple momentum caused by the
commitment of a large number of re-
searchers and resources [17] (also known
as a ‘‘scientific bandwagon’’) [24] can
distort public communication on this issue
and thus public expectations [25]. These
distortions, together with enthusiasm from
funding entities, media coverage, and the
positioning of WGS and personalized
medicine as a tool for regional economic
growth [26], may influence our thinking
on how best to deploy WGS technologies
within health care systems.
Health policy deliberations need to be
aware of these forces and their impact on
the representations and perceptions of the
value and cost of high profile technology
like WGS. Spectacular technological ad-
vances have led to the dramatic decrease
in cost of sequencing [27], and this
decrease is often treated as sufficient
justification for its clinical application. A
US$1,000 price tag does bring WGS data
within reach for many. However, WGS
brings with it more costs—both monetary
and beyond—than the charges for se-
quencing. Upstream costs include creating
and validating the institutional and tech-
nological infrastructure for both the pro-
duction and storage of sequence data that
follow clinical laboratory standards and for
the interpretation and confirmation of
WGS results. The latter can frequently
be laborious, expensive, and highly time-
consuming. This has led many to joke
about of the US$1,000 genome and the
US$1 million interpretation [28].
Moreover, the downstream costs of a
diagnostic intervention can far outweigh
the upfront costs of the initial test [29].
This is especially true for tests that
generate a large amount of information,
and potentially large amounts of ambigu-
ous information as well as false positives
and incidental findings. The downstream
resource and health consequences of
ambiguous results are substantial and can
include clinical follow-up, additional tests,
and also unnecessary surveillance and
interventions—as is seen with other tech-
nologies, such as has happened, for
example, with the introduction of prostate
specific antigen (PSA) testing [9]. In
clinical practice, there is rarely such a
thing as a ‘‘low cost’’ test; the ‘‘low cost
high value’’ WGS may be rarer still.
Clinical Utilization of WGS
Lower cost sequencing has fostered the
idea that there will be a high degree of
both consumer and clinical utilization of
WGS [3,30], as captured by the suggestion
that soon ‘‘everyone will be sequenced’’
[31]. There is little doubt that the
application of WGS in the research setting
is shedding new light on the molecular
mechanisms that influence health, disease,
and drug response. Also, there are signif-
icant social forces, particularly in the US
and UK where this field is often cast as a
potential engine of economic growth,
driving its clinical implementation [4].
Nevertheless, we need to bear in mind
that its uses in research do not necessarily
imply equivalent utility in the clinic. Utility
in a clinical setting depends on many—
and very different—factors, and must take
into account not only such performance
characteristics as sensitivity, specificity,
and positive and negative predictive value,
but also demonstration of beneficial im-
pact of using the test on patients’ health, or
on health services delivery. Failure to do so
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can trigger overt harm to patients in
addition to excessive cost to the health
care system [9].
It is clear that genomic sequencing will
prove to be a useful diagnostic approach in
specific situations [32]. For example, it will
allow the identification of a causative
mutation in patients with genetically
heterogeneous disorders (in which muta-
tions in many different genes can result in
a similar phenotype), in children with
complex unexplained co-morbidities, and
in individuals with strong family histories
of an enigmatic disorder. Although more
work needs to be done to demonstrate
clinical utility, promising opportunities
exist in the realm of cancer treatment.
For example, genome-scale sequencing of
tumors may provide important informa-
tion regarding the mutations that drive a
patient’s malignancy and so guide their
treatment [33], with one of the potential
beneficial by-products of WGS being drug
dosing and pharmacogenomics applica-
tions.
In contrast to these successes, there are
few data and little compelling support to
suggest that WGS of individuals with
common diseases will result in clinically
actionable information, or that whatever
benefits are accrued might outweigh the
burdens of, for example, false positive
results or the follow-up investigation of
ambiguous results. Common diseases
that, by definition, affect the greatest
number of individuals, have a relatively
low genetic component, placing an
inherent ceiling on the usefulness of
genomic information to meaningfully
inform individuals regarding these disor-
ders [34]. This in itself supports the
adoption of a cautious, if not outright
skeptical, perspective regarding the im-
pact of WGS on the clinical management
of common diseases and thus more
modest expectations of a revolution in
medical care, at least in the short term.
As mentioned above, there is a high risk
of generating a lot of ambiguous informa-
tion when a tremendously broad test such
as WGS is used clinically. It is a well-
supported tenet of medical practice that
overly broad testing can cause consider-
able harm owing to the inevitable trade-off
between sensitivity and specificity [35]
requiring such testing to be carefully used.
This caution regarding the use of non-
specific testing has particular resonance
when considering the application of WGS
in healthy members of the population. In
the public health setting, the probability
that any specific variant is meaningful is
low due to the rarity of disorders with a
strong genetic cause in the general popu-
lation.
While the balance of the clinical benefits
and harms of WGS in otherwise healthy
people may not currently support its
adoption as a diagnostic tool, some
communities outside of health care are
already utilizing sequencing technology
(via the private sector) to provide answers
to questions that are not credibly avail-
able in any other manner, perhaps most
notably in genealogy. The meaningful-
ness of WGS to these communities is
difficult to refute. Advocates of WGS,
and personalized medicine more gener-
ally, often promote the idea that more
data is always better and that ‘‘knowl-
edge is power’’ [36], and that genomics
will inevitably empower patients and
promote individual control over health
(Box 1). The push to embrace WGS is
inextricably linked to this vision of
empowerment, particularly in the con-
text of genetic risk information [37].
However, the provision of such informa-
tion will create clinical challenges, in-
cluding straining the physician/patient
relationship by shifting more responsibil-
ity and expectations to the patient
[38,39]. More fundamentally, there is
little evidence to support the basic
premise implied by the empowerment
rhetoric—namely that individuals will
use genomic risk information to adopt a
healthier lifestyle and, thus, reduce their
risk for chronic diseases. In fact, existing
research tells us that individuals do not
alter their behaviour on the basis of
genetic risk information [40–43]. Indeed,
promoting meaningful behaviour change
is tremendously difficult, particularly on
a population level [44]. Hence, the value
of WGS in this space—that is, in the
context of empowerment—is conditional
upon the development of effective be-
haviour change interventions.
In the context of utility it is also worth
reflecting on the predictions of high
uptake among the general population.
Previous experience with high-through-
put DNA technologies suggests the need
for caution and an expectation that the
utility of platform technologies such as
WGS will be highly variable. Microar-
rays have played an important role in the
diagnosis of developmental disorders, but
their use in pharmacogenetics has thus
far been clinically disappointing, in part
due to an absence of evidence that they
produce convincing outcomes. Array-
based susceptibility testing for common
diseases has also failed to garner clinical
adoption, and where it has been com-
mercialized as direct-to-consumer servic-
es there has been only modest uptake
[45]. Despite claims that inexpensive
Box 1. The Rhetoric of Empowerment
The ideas of empowerment and personal choice are significant aspects of the
popular culture messaging around WGS, particularly in the context of
personalized medicine. Below are a few examples of how this message is framed
in various domains.
‘‘The success of personalized medicine will come about only when we each take
responsibility for our health. Health care providers can help, but they cannot drive
your bus… [there are] things you can do now to take full advantage of the
potential for personal empowerment. If you follow these recommendations, you
will truly be on the leading edge of this new revolution’’ [48].
‘‘WGS is not a panacea for all that ails humankind, but a powerful new tool that
can catalyze our understanding of the genome and thereby empower patients’’
[49].
‘‘Advances in genomic and molecular medicine hold the potential to radically
transform human health by enabling much more precise prediction, prevention,
and treatment of disease on an individual level… The Center’s mission is to
empower patients to understand their unique health needs…’’ [50].
‘‘It [personalized medicine] is proactive and participatory, engaging patients in
lifestyle choices and active health maintenance to compensate for genetic
susceptibilities’’ [51].
‘‘There will be a greater emphasis on the physician-patient relationship as we
team together to develop more accurate and personalized care plans. Our
ultimate goal is to empower our patients and our community towards greater
health’’ [52].
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WGS will lead to widespread use on a
population level, there is little evidence,
at this stage, to suggest that it will be
widely adopted [46].
Moving Forward
WGS holds undeniable promise as a
diagnostic tool in certain clinical situa-
tions, and might also contribute to im-
proving public health if used judiciously on
an evidence-base basis [47]. However, its
promise, coupled with the cautions noted
above, argue for careful consideration as
we seek to craft policy regarding its
transition from research to clinical prac-
tice.
Characterizing the benefits and costs of
specific applications of WGS will need to
take full account of the upfront investment
and downstream clinical practice implica-
tions. It will require the comparison of
WGS-augmented care with current clini-
cal practice and with care pathways that
utilize alternative testing technologies.
Remembering that inefficient use of
limited resources reduces the scale and
quality of health care available for others,
health systems will need to assess carefully
the benefits of WGS that they wish to pay
for and the quality of evidence they
require to accept the benefits as demon-
strated. Given the low unit cost of WGS,
the risk of moving quickly from research
and clinical practice may be substantial,
and health systems will need to consider
how to protect themselves from the costs
of over-testing and the potential burden of
false positives, in the absence of clear value
criteria.
Clarifying the evidence hurdles facing
WGS also will benefit the research com-
munity. By signaling clearly the type of
evidence required to support a decision to
provide funding to cover the costs of
testing and related services, health systems
will enable researchers and investors to
prioritize alternative research investment
opportunities to focus on those that have
the greatest value.
Conclusion
There are, of course, many other
issues that need to be considered as
WGS becomes more common, including
concerns about genetic discrimination,
issues of consent (e.g., to what degree
should or could biological relatives be
engaged in the consent process), and the
direct-to-consumer provision of WGS.
In addition, there are likely to be a
range of translation issues, such as
uncertainty about the role and impact
of intellectual property (Box 2). Also,
the diversity of health insurance systems
and health economic policies in various
countries will undoubtedly affect the
way new technology is incorporated
into clinical practices. But while these,
and other, issues require further reflec-
tion, we already know enough to
provide advice for the framing of health
policy.
Rapid, lower-cost WGS is a promising
research tool with unproven clinical
utility, except in a small set of very
specific situations. The journey from
bench to bedside is one we should travel
with care. Caution is warranted because
we must reconcile diverse tensions—the
commercial appetite for market growth
versus the need for prudent health care
expenditure, the research community’s
enthusiasm for genomic science versus
professional, and public skepticism about
personalized medicine. Due diligence
should attend to the many competing
demands on health care expenditure and
biomedical R&D, to the ambiguous
effects of new technologies, and to our
well-justified ambivalence about the util-
ity of an over-abundance of clinical data
in the absence of evidence to establish
actual clinical value. The scale and pace
of adoption of this powerful new tech-
nology should be driven by clinical need,
clinical evidence, and a commitment to
put patients at the centre of health care
policy.
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Box 2. WGS and the Impact of Intellectual Property
While intellectual property (IP) complexities may arise that concern WGS, they
are unlikely, for a number of reasons, to come from gene-based patent claims
[53,54]. The policy rationale for exclusive rights in DNA-based diagnostics has
historically been weak [55,56]. And the recent decision by the Supreme Court of
the United States, which declared that a naturally occurring DNA segment is a
product of nature and therefore not patentable, will weaken patent related
hurdles to WGS [57].
However, other forms of IP present challenges, such as data-hoarding practices in
both academia and industry. Access to genomic data held in the private
databases of both sectors is needed to advance science and to interpret
diagnostic tests. Myriad Genetics’ proprietary database, for example, is based on a
million tests performed when Myriad’s patent rights were presumed valid [58].
Lack of access to this data prevents the external validation of clinical
interpretation, verification testing, and clinical research on BRCA gene mutations.
Inaccessible data will also limit the comprehensiveness of core genomic
databases, impoverishing the public domain. In response, innovative models
are emerging at, for example, public research institutions to re-create public
domain data resources where external validation is possible [59].
Translating new data into useful clinical information will require data-sharing,
interoperability, and database infrastructure (and stable funding to ensure
reliability, access, and curation). Interoperability includes legal regimes that
accommodate differences in privacy laws and informed consent to enable the use
of stored datasets. Patient groups are becoming increasingly active in
establishing platforms through which patients and other individuals may
contribute their own genetic and other health information [60]. Patients and
consumers need to be at the table when decisions about pooling and sharing
data are made. Widespread data sharing also entails risks to privacy. Therefore
policies to promote data sharing will require a legal infrastructure to prevent re-
identification and to protect privacy.
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